Literature DB >> 18619590

The effect of an iron (III) chelator, silybin, on the proliferation and cell cycle of Jurkat cells: a comparison with desferrioxamine.

Marjan Gharagozloo1, Zahra Khoshdel, Zahra Amirghofran.   

Abstract

Silybin is a flavonoid with antioxidant and free radical scavenging abilities. Silybin also acts as an iron chelator by binding Fe (III). The present study was undertaken to assess the biological effects of silybin on T leukemia cells in the presence or absence of iron and compare its effects with a well-known iron chelator; desferrioxamine. In these experiments, we studied the growth capacity of Jurkat while varying iron availability in the environment. Desferrioxamine significantly inhibited growth and proliferation of Jurkat cells, blocking treated cells in the G0/G1 phase and inducing apoptosis. In contrast, silybin showed a bimodal effect, inducing cell proliferation at lower concentrations whereas inhibition of DNA synthesis and significant cell death was observed at higher concentrations. Chelation of Fe totally abrogated antiproliferative, cytotoxic and apoptotic effects of desferrioxamine on Jurkat cells. Conversely, the silybin-Fe complex had no appreciable effect on its antiproliferative and cytotoxic activities. The cytotoxic effect of desferrioxamine was also prevented in iron-loaded Jurkat cells; however, the effect of silybin on the growth and viability of iron-loaded cells was similar to the effect of its iron complex on untreated Jurkat cells. Despite the Fe chelating activity of silybin that suggests its possible application in chelation therapy of chronic iron overload, the biological effects of silybin on Jurkat cells are different than those of desferrioxamine, probably due to antioxidant activity of silybin, which causes pro-oxidant effect via iron-catalyzed oxidation with the subsequent generation of reactive oxygen species.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18619590     DOI: 10.1016/j.ejphar.2008.03.059

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  24 in total

Review 1.  Silybin and the liver: from basic research to clinical practice.

Authors:  Carmela Loguercio; Davide Festi
Journal:  World J Gastroenterol       Date:  2011-05-14       Impact factor: 5.742

2.  Bp44mT: an orally active iron chelator of the thiosemicarbazone class with potent anti-tumour efficacy.

Authors:  Y Yu; Y Suryo Rahmanto; D R Richardson
Journal:  Br J Pharmacol       Date:  2012-01       Impact factor: 8.739

3.  Effects of iron chelators, iron salts, and iron oxide nanoparticles on the proliferation and the iron content of oligodendroglial OLN-93 cells.

Authors:  Michaela Hohnholt; Mark Geppert; Ralf Dringen
Journal:  Neurochem Res       Date:  2010-05-14       Impact factor: 3.996

Review 4.  Antimetastatic efficacy of silibinin: molecular mechanisms and therapeutic potential against cancer.

Authors:  Gagan Deep; Rajesh Agarwal
Journal:  Cancer Metastasis Rev       Date:  2010-09       Impact factor: 9.264

5.  Free radical scavenging activity of silibinin in nitrite-induced hemoglobin oxidation and membrane fragility models.

Authors:  Bushra H Marouf; Munaf H Zalzala; Ihab I Al-Khalifa; Tavga A Aziz; Saad A Hussain
Journal:  Saudi Pharm J       Date:  2011-03-21       Impact factor: 4.330

6.  Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis C.

Authors:  Roy L Hawke; Sarah J Schrieber; Tedi A Soule; Zhiming Wen; Philip C Smith; K Rajender Reddy; Abdus S Wahed; Steven H Belle; Nezam H Afdhal; Victor J Navarro; Josh Berman; Qi-Ying Liu; Edward Doo; Michael W Fried
Journal:  J Clin Pharmacol       Date:  2009-10-19       Impact factor: 3.126

7.  Iron chelator-induced apoptosis via the ER stress pathway in gastric cancer cells.

Authors:  Jung Lim Kim; Dae-Hee Lee; Yoo Jin Na; Bo Ram Kim; Yoon A Jeong; Sun Il Lee; Sanghee Kang; Sung Yup Joung; Suk-Young Lee; Sang Cheul Oh; Byung Wook Min
Journal:  Tumour Biol       Date:  2016-01-23

8.  Protective Role of Silymarin and Deferoxamine Against Iron Dextran-induced Renal Iron Deposition in Male Rats.

Authors:  Mehdi Nematbakhsh; Zahra Pezeshki; Behjat Alsaadat Moaeidi; Fatemeh Eshraghi-Jazi; Ardeshir Talebi; Hamid Nasri; Shahrzad Baradaran; Marjan Gharagozloo; Tahereh Safari; Maryam Haghighi
Journal:  Int J Prev Med       Date:  2013-03

9.  Effect of iron deficiency on c-kit⁺ cardiac stem cells in vitro.

Authors:  Dongqiang Song; Yuanmin Li; Jiatian Cao; Zhihua Han; Lin Gao; Zuojun Xu; Zhaofang Yin; Guifang Wang; Yuqi Fan; Changqian Wang
Journal:  PLoS One       Date:  2013-06-10       Impact factor: 3.240

10.  Effects of oral iron chelator deferasirox on human malignant lymphoma cells.

Authors:  Jong Gwon Choi; Jung-Lim Kim; Joohee Park; Soonwook Lee; Seh Jong Park; Jun Suk Kim; Chul Won Choi
Journal:  Korean J Hematol       Date:  2012-09-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.